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Background   
There is little evidence to guide pharmacological treatment in adults with Down syndrome 
and Alzheimer’s dementia (AD).  
 
Aim   
To investigate the effect of cholinesterase inhibitors or memantine on survival and function 
in adults with Down syndrome and AD. 
 
Methods   
Clinical cohort of 310 people with Down syndrome diagnosed with AD collected from 
specialist community services in England with naturalistic longitudinal follow-up.  
 
Results 
Median survival time (5.59 years; 95% confidence interval 4.67, 6.67) for those on medication 
(n=145, mainly cholinesterase inhibitors) was significantly greater than for those not 
prescribed medication (n=165) (3.45 years, 95% confidence interval 2.91, 4.13; log rank test 





Cholinesterase inhibitors appear to offer benefit in people with Down syndrome and AD that 
is comparable to sporadic AD; a trial to test the effect of earlier treatment (prodromal AD) in 
Down syndrome may be indicated. 
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The life expectancy of people with Down syndrome has increased greatly over the past several 
decades and many people with the condition now live into older age.1,2 People with Down 
syndrome have a higher risk of developing Alzheimer’s dementia (AD) than the general 
population.3 There is good evidence that cholinesterase inhibitors (donepezil, rivastigmine, 
or galantamine) and memantine, a non-competitive NMDA-receptor antagonist, can improve 
cognitive function and behaviour in non-intellectually disabled people with AD4,5 however 
people with Down syndrome have been excluded from most trials of anti-dementia drugs and 
the evidence that they are effective in this group remains inconclusive.6-9 
 
The aim of this study is to determine the effect of cholinesterase inhibitors or memantine on 
survival and cognitive and adaptive function in a large clinical cohort of people with Down 






Data were obtained from the Aging with Down Syndrome and Intellectual Disability (ADSID) 
database, a research database conceived following the regular meetings of a regional 
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Dementia in Intellectual Disability special interest group.10 The ADSID database contains the 
clinical information of over one thousand adults with intellectual disability who have been 
assessed in specialist memory clinics for adults with intellectual disability. Data were collected 
by the authors from the clinical records held by Psychiatry of Intellectual Disability community 
teams across London and the south of England. Demographic and clinical details were 
extracted from the patient notes, pseudonymised at source, and added to the database which 
is held securely at University College London. Data include, degree and aetiology of 
intellectual disability, physical and psychiatric co-morbidities (with a particular emphasis on 
those that are common in people with Down syndrome and those that are related to cognitive 
functioning such as thyroid disorder, past or current history of depression, epilepsy, and 
sensory impairment), and psychotropic drug prescription. Dates of clinical assessments and 
the results of standardized cognitive tests are also recorded. Many of those included have 
been under regular clinic follow-up contribute data from several sequential assessments. 
Date and cause of death is recorded, where applicable. The database contains information 





Ethical approval for use of the ADSID database in research studies was obtained from the 
Newcastle and North Tyneside 1 Research Ethics Committee (reference 10/H0906/30). 
Special permission was received from the National Information Governance Board for Health 
and Social Care Ethics and Confidentiality Committee to process patient identifiable 
information at source without consent (reference ECC 5-04(h)/2010). The Caldicott Guardian 





We included all people in the ADSID database with Down syndrome and a diagnosis of AD 
made after January 2000. Data collection finished in 2013. A record of Down syndrome in the 
person’s clinical notes or results of genetic tests indicating Down syndrome was taken as 
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evidence of the condition. The diagnosis of dementia was made by the person’s own clinical 
team and the assessment process was determined by local protocols, as there is no agreed 
standard for dementia assessment in Down syndrome. In line with current best practice 
guidance, diagnostic assessments were expected to have been undertaken by an experienced 
clinician and to include medical history, neuropsychiatric assessment, and physical and 
mental state examination, and exclusion of other causes of decline.11 If there was uncertainty 
about the diagnosis of Down syndrome or AD the participant was excluded from the study. 
We collected a minimum data set for each participant and excluded those for whom 
insufficient data were available.  
 
The cohort was divided into groups based on prescription of medication for dementia, first 
into those who had been prescribed medication and those who had not, then by medication 
class and drug prescribed. A separate category was created for individuals who had been 
prescribed both cholinesterase inhibitors and memantine. The dates of starting, stopping, and 
switching medication were recorded, where available. Where the date of starting medication 
was not known, the date of dementia diagnosis was considered the most likely date of 
prescription and used as a proxy. 
 
Outcomes and measures 
 
The Dementia Questionnaire for People with Learning Disabilities (DLD) was used to measure 
baseline and changes in cognitive and adaptive function.12 The DLD is a routinely-used 
standardised informant-based questionnaire consisting of 50 items grouped into 8 categories 
which the informant is asked to rate on a linear scale based on observations made over the 
preceding 6 months. Completing the DLD yields two sub-scores; a sum of cognitive scores 
(SCS, covering memory and orientation); a sum of social scores (SSS, covering aspects of 
behaviour and adaptive function). Higher scores indicate more severe impairment. The DLD 
is a sensitive tool in tracking changes over time in people with Down syndrome and cognitive 
decline, and is recommended as a tool to supplement clinical assessment in people with 
intellectual disability in the National Institute for Health and Care Excellence dementia 
pathway.13-15 Baseline score was defined as the DLD at the point of diagnosis (or the last 
recorded DLD prior to diagnosis), 1st assessment and 2nd assessment DLD scores were the first 
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and second subsequent clinical assessments after a diagnosis of dementia, which occurred at 
variable times after diagnosis based on local clinical policies and individual need. Clinicians 
were also asked to rate cases as early, middle, or late stage dementia based on the overall 
clinical picture and their clinical judgement. 
 
Where available, the latest recorded DLD score prior to (or at) dementia diagnosis and the 
DLD scores at first and second follow-up appointments after the diagnosis were compared 




Numerical data were summarised using mean, standard deviation or median and range 
depending on data distribution. Categorical data were summarised using count and 
percentages. We carried out simple analyses using the independent t-test or Mann-Whitney 
U test, and Chi-square test to compare the groups defined by dementia medication status. 
We used multivariable linear regression to assess the difference in DLD score between the 
groups, adjusting for pre-treatment values.16 
 
The primary outcome measure was death. Survival time was defined as the time in years 
between the date of diagnosis of AD and the date of death. Participants were censored if they 
were alive or dead with no known date of death. We used the Kaplan-Meier method to 
estimate the median survival times.  Survival time was defined as the time between dementia 
diagnosis and last assessment or date of death. Participants who were alive were censored at 
the date of the last clinic assessment. Participants who died were censored at the date of 
death. We censored the small number of participants who had died but for whom date of 
death was missing, at the date of the last clinic assessment. We used log-rank rank tests to 
evaluate the evaluate the survival distributions of different groups (anti-dementia medication 
status and medication class).17 
 
We examined the effect of the following pre-defined set of potential confounding variables 
on survival: age at dementia diagnosis; sex; degree of intellectual disability; antipsychotic use; 
past history of depression (recorded diagnosis or prescription of anti-depressant medication); 
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current or past history of thyroid disease (recorded diagnosis or prescription of thyroid-
specific medication); history of epilepsy preceding dementia diagnosis; and vision or hearing 
impairment. Factors associated with death were analysed with Cox‘s proportional hazard 
model.18 We used 20% as the threshold for statistical significance in the univariable analysis 
to identify the variables that indicate a reasonable degree of association with the outcome 
and which were then added to the multivariable model.19 We also used the backward 
elimination selection procedure with a 20% significance level to verify the stability of the 
variable selection process.20 The final multivariable model included site, age at dementia 
diagnosis, sex, and degree of intellectual disability. We tested the validity of the proportional 
hazard assumption by plotting log-minus-log survival curves and carrying out Schoenfeld 
tests.18 
 
Statistical analyses were performed using Stata V.13 (StataCorp LP, College Station, Texas, 
USA). No formal sample size calculation was carried out. It is recommended that at least 10 
events per estimated parameter are required in order to avoid the problem of overﬁtting, 
which can arise if the model contains fewer events compared with the number of variables in 




Data were collected from 18 Psychiatry of Intellectual Disability clinical teams across 4 broad 
geographic regions. Three-hundred and ten individuals with Down syndrome and dementia 
were included (174 male (56.1%)). Approximately one-third (35.2%) of the cohort had mild-
moderate intellectual disability (intelligence quotient range 35-69), one-third (33.2%) had 
severe-profound intellectual disability (intelligence quotient <35), and the degree of 
intellectual disability was not recorded in the remainder (31.6%). 
 
Descriptive characteristics of study participants 
 
145 (47%) of the study participants were prescribed anti-dementia medication and 165 (53%) 
were not prescribed such medication (Table 1). Those prescribed anti-dementia medication 
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were younger at diagnosis (53.8 years vs. 56.6 years, p=0.0003) and a greater proportion had 
mild-moderate intellectual disability (p<0.0001). 
 
Total DLD Score, SCS, and the SSS at diagnosis, were significantly higher in the group not 
prescribed medication, indicating that this group had more severe symptoms of dementia at 
diagnosis. A greater proportion of those prescribed anti-dementia drugs were assessed as 
having early dementia by clinicians, and a greater proportion in the non-prescribed group had 
middle or late dementia, although the differences in these proportions were not statistically 
significant. 
 
There was no significant difference in gender or rates of measured co-morbidities between 
those prescribed and not prescribed anti-dementia medication. 
 
[TABLE 1 near here] 
 
Impact of acetylcholinesterase inhibitors or memantine on survival 
 
The Kaplan-Meier survival curves following diagnosis of dementia for those prescribed and 
not prescribed anti-dementia drugs show a significant difference in survival time between 
those prescribed and not prescribed anti-dementia medication (Figure 1a). Median survival 
time on any anti-dementia drug was 5.59 years (95% confidence interval 4.67 to 6.67) whilst 
median survival time of those not prescribed any anti-dementia drug was 3.45 years (95% 
confidence interval 2.91 to 4.13; log-rank test p<0.0001). Prescription of cholinesterase 
inhibitors, either alone or in combination with memantine, conferred a survival advantage; 
median survival time for those prescribed an acetylcholinesterase inhibitor was 6.15 years 
(95% confidence interval 4.44 to .), and median survival time of those people prescribed both 
memantine and an acetylcholinesterase inhibitor was 5.31 years (95% confidence interval 
3.65 to 6.10). In contrast, median survival time on no medication was 3.45 years (95% 
confidence interval 2.91 to 4.13; log-rank test p=0.0001) (Figure 1b). 
 
[FIGURES 1a AND 1b NEAR HERE] 
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Factors that conferred a higher hazard of death during the observation period were, increased 
age at diagnosis, more severe intellectual disability, and having pre-existing epilepsy 
(supplementary data table 1). These were entered into a multivariable Cox regression (with 
region and sex as fixed factors) to investigate the effect of different variables on survival after 
a diagnosis of dementia (Table 2). 
 
Those who were prescribed anti-dementia medication had a lower risk of death than those 
who were not prescribed anti-dementia medication, but this association was not statistically 
significant after accounting for confounding variables (adjusted hazard ratio 0.65, 95% 
confidence interval 0.32 to 1.32, p=0.235). There were no statistically significant differences 
between different classes of anti-dementia medication, although prescription of 
cholinesterase inhibitors (either alone or in combination with memantine) was consistently 
associated with a lower hazard ratio of death than prescription of memantine alone. There 
was no difference in hazard ratio of death between the different cholinesterase inhibitors. 
We conducted a sensitivity analysis where the regression model did not include level of 
intellectual disability as this variable included a high degree of missing data; in this analysis 
(including 254 people) the adjusted hazard ratio of death for those prescribed anti-dementia 
medication was 0.45 (95% confidence interval 0.25 to 0.82, p=0.009). 
 




The median time between the baseline and first assessment after diagnosis was 191 days (6.1 
months; inter-quartile range 139-303 days) and between first and second assessments was 
183 days (5.9 months; inter-quartile range 166-233 days). The cognitive score (SCS) was 
significantly lower in the group that received medication at first follow-up assessment 
(indicating better cognitive functioning); this advantage was lost by the time of the second 
follow-up appointment. The sum of social scores (SSS, indicating functional abilities) showed 
no differences between the groups (table 3). 
 





Summary of results 
 
This observational study is the first to investigate survival of people with Down syndrome and 
AD who were prescribed cholinesterase inhibitors and/or memantine. Survival analysis 
demonstrates an advantage in patients prescribed medication over patients who were not 
prescribed medication for AD, however when we accounted for the effect of confounders in 
a Cox regression model, the effect of anti-dementia medication prescription on survival was 
mitigated and became non-significant.  
 
There was a trend in adjusted analyses for a survival advantage in those prescribed 
cholinesterase inhibitors compared to prescribed memantine alone, who had a tendency to 
die sooner, although this finding needs to be interpreted with caution given the small number 
of people in the analysis. There were no significant differences between the different 
cholinesterase inhibitors (donepezil, galantamine, and rivastigmine). Performing a sensitivity 
analysis which excluded degree of intellectual disability from the model enabled a larger 
sample size to explore the effect of missing data, although at the expense of removing a factor 
likely to influence survival, and in this analysis the positive effect of anti-dementia drugs on 
survival time was significant. 
 
We considered the potential symptomatic benefit of cholinesterase inhibitors and 
memantine using the DLD, a validated carer-rated measure of function over several domains. 
The cognitive subscale of the DLD, covering short-term memory, long-term memory, and 
orientation, showed a significantly difference at the first follow-up assessment (on average 6 
months after the baseline) in favour of those prescribed medication. This difference was not 
mirrored by differences in the social (behaviour) subscale and had been lost by the second 
follow-up assessment (on average 12 months after baseline). 
 
There were conspicuous differences in rates of prescribing between the four regions from 
which data were collected. Some of these differences may be accounted for by the different 
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clinical characteristics of people seen by each team, although as each community team could 
be expected to see a broadly similar group of patients, the data also highlight likely variation 
in practice. This is perhaps not surprising given the lack of available evidence in this area on 
which clinicians can base decisions. There are currently no national- or regional-level data in 
the UK that compare rates of diagnosis of dementia or prescribing of anti-dementia drugs in 
people with intellectual disability, and the prevalence of prescribing is likely to have changed 
over the time period that our data were derived.  The results suggest that care pathways 
should be standardised for this group to ensure equitable treatment, given some evidence of 
early benefit at cognitive level. 
 
Comparison with existing literature 
 
The effect of anti-dementia drugs on survival in people without Down syndrome is uncertain; 
some studies report increased survival in people prescribed anti-dementia drugs,21,22 yet 
other studies do not.23,24 A underlying mechanism by which anti-dementia medications might 
reduce mortality has not been established but it has been hypothesised that the effect is 
mediated by protective effects of the drugs on atherosclerotic cardiovascular risk.25 However 
the relevance of such a mechanism to people with Down syndrome might be offset by the 
relatively low observed rates of atherosclerotic disease in this group.26  
 
Our results accord with a number of existing small studies that have explored the 
symptomatic benefit of cholinesterase inhibitors on people with Down syndrome and AD and 
shown potential for limited benefit of these drugs.27-31 The benefit of cholinesterase inhibitors 
has been reported to occur within the first 3-6 months of treatment,27,32 consistent with our 
own results. Our findings are also in keeping with recent evidence from clinical studies of 
cholinesterase inhibitors in adults with sporadic AD, also showing a larger response during 
the first 6 months of treatment,33 while donepezil treatment decreased the annual rate of 
hippocampal atrophy in a recent randomized controlled trial in prodromal AD.34 Better 
cognitive functioning could permit people to attend to and better manage their physical 
health, thus improving survival. 
 
Strengths and limitations of the study 
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This study adds to the limited evidence base on the effectiveness of anti-dementia medication 
in people with Down syndrome and AD. It is the first study to provide outcome data 
comparing different classes of anti-dementia drugs, and on the use of galantamine in this 
population. Data were collected over several years from a range of real-world clinical services 
covering urban and rural locations. The people included have a range of concomitant health 
issues as might be expected in a population of aging adults with Down syndrome and are likely 
to be representative of those who are known to specialist community services nationally. 
 
The widespread acceptance and use of cholinesterase inhibitors and memantine in people 
with Down syndrome and AD in contemporary clinical care35 makes it difficult to justify a 
controlled drug trial where some participants do not receive these drugs and the 
observational design of our study is therefore appropriate in this context. Our results suggest 
significant cognitive benefit during the initial 6 months of treatment of cholinesterase 
inhibitors in individuals with Down syndrome who have been diagnosed with AD, which 
requires further exploration. 
 
There are certain limitations to this observational study. It is not possible to determine a 
causal relationship between prescription of cholinesterase inhibitors and survival. There were 
significant baseline differences between the groups prescribed and not prescribed anti-
dementia medication. Those who were not prescribed medication were older, more likely to 
have severe/profound intellectual disability, and had more severe dementia symptoms at 
baseline. Although we adjusted for major measured confounders in the analysis, due to lack 
of randomisation the results might be subject to residual confounding and influenced by 
unknown or unmeasured variables that could account for some of the differences associated 
with medication treatment we have observed. 
 
There are difficulties in recognising and diagnosing dementia in people with Down syndrome 
who have pre-existing cognitive impairment. It is possible that a small number of people may 
have been misdiagnosed, however we have shown in a previous study that clinical diagnoses 
of dementia made in these specialist teams are valid and reliable.10 
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Owing to this being a study using routine clinical data, there were missing data and variation 
in time-points of assessment that limited our analyses and the strength of the conclusions 
that we are able to draw. We did not have data on the dose of medication or compliance with 
treatment. The low numbers of people prescribed memantine prevent us from drawing 
strong inferences based on the obtained results; however, our results are in keeping with an 
RCT that has shown that this drug is not effective for AD in Down syndrome.9 
  
Further work is needed to investigate the effect of all anti-dementia drugs on a broader set 
of cognitive and functional outcomes, including longer-term outcomes such as time to 




While we await advances in the understanding of the pathophysiology of AD relevant to 
people with Down syndrome that might permit interventions to delay the onset or even 
prevent it,3 identifying optimum treatment for those living with the disease must be a priority. 
Notwithstanding the limitations of this study, the results of this work lend support to the 
prescription of cholinesterase inhibitors as first-line pharmacological intervention for people 
with Down syndrome and AD and suggest that they might increase survival and reduce the 
rate of cognitive decline in the early stages after diagnosis. Although people with Down 
syndrome are likely to have co-morbid health conditions as they age, cholinesterase inhibitors 
are relatively safe in this population,27,36 and anecdotal evidence suggests that adverse side-
effects should not be a barrier to prescription if supplemented by regular monitoring.  
 
AD is a major concern for people with Down syndrome who are increasingly living into older 
age. Dementia has wide-ranging implications for the person affected, their family and paid 
carers, and the system of medical and social supports that are likely to require as the disease 
progresses.37 Early diagnosis and improved care pathways are likely to impact positively on 
the provision of other aspects of care. A clinical trial of treatment with cholinesterase 
inhibitors during the early symptomatic stages of cognitive decline in Down syndrome before 
a formal dementia diagnosis should be considered to test whether early response can be 
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maximized, and to determine if cognitive benefit is related to functional improvement and is 
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Table 1 - Comparison of baseline demographic and clinical characteristics by anti-dementia 
medication status of the study participants (n=310) 
  Prescribed medication  
 Summary 
statistic 
No (n=165) Yes (n=145) p-value* 
Follow-up (years) Mean (SD) 5.61 (4.97) 4.79 (4.49) 0.0639 
Age at diagnosis (n=310) Mean (SD) 56.55 (6.40) 53.81 (6.63) 0.0003 
Gender (n=310)    0.290 
Male (n=174) n (%) 88 (51%) 86 (49%)  
Female (n=136) n (%) 77 (57%) 59 (43%)  
Intellectual Disability (n=212)    <0.0001 
Mild (n=51) n (%) 6 (12%) 45 (88%)  
Moderate (n=58) n (%) 19 (33%) 39 (67%)  
Severe - profound (n=103) n (%) 57 (55%) 46 (45%)  
Region (n=310)    <0.0001 
Region A (n=66) n (%) 32 (48%) 34 (52%)  
Region B (n=85) n (%) 6 (7%) 79 (93%)  
Region C (n=32) n (%) 8 (25%) 24 (75%)  
Region D (n=127) n (%) 117 (92%) 10 (8%)  
Thyroid disease (n=175)    0.079 
Yes (n=86) n (%) 51 (59%) 35 (41%)  
No (n=89) n (%) 64 (72%) 25 (28%)  
Epilepsy (n=262)    0.172 
Yes (n=52) n (%) 31 (60%) 21 (40%)  
No (n=210) n (%) 103 (49%) 107 (51%)  
Sensory impairment (n=176)    0.692 
Yes (n=122) n (%) 85 (70%) 37 (30%)  
No (n=54) n (%) 36 (67%) 18 (33%)  
Depression (n=162)    0.883 
Yes (n=27) n (%) 17 (63%) 10 (37%)  
No (n=135) n (%) 87 (64%) 48 (36%)  
Dementia severity at diagnosis (n=52)    0.255 
Early (n=38) n (%) 18 (47%) 20 (53%)  
Middle (n=13) n (%) 9 (69%) 4 (31%)  
Late (n=1) n (%) 1 (100%) 0 (0%)  
DLD score at diagnosis      
Sum of Cognitive Scores (n=136) Mean (SD) 30.54 (9.60) 25.35 (11.00) 0.0247 
Sum of Social Scores (n=133) Mean (SD) 28.32 (13.17) 20.84 (10.60) 0.0126 
Total (n=139) Mean (SD) 55.92 (21.46) 45.04 (20.30) 0.0266 
 
*p-values obtained from: two-sample independent t-test, Mann-Whitney U test, and Chi-



















Figure 1a - Kaplan-Meier survival curve of those prescribed anti-dementia medication and 




Figure 1a - Kaplan-Meier survival curve of those prescribed anti-dementia medication and 
those not prescribed anti-dementia medication (by drug type) 
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Table 2 - Adjusted and unadjusted hazard ration (HR) for death, derived from a Cox 
regression model   
 Unadjusted analysis Adjusted analysis* 
 HR (95 % CI) p-value HR (95 % CI) p-value 
On medication (n=255)     
Yes 0.46 (0.33, 0.66) <0.0001 0.65 (0.32, 1.32) 0.235 
No Reference    
Medication class (n=303)  0.0002  0.0788 
Memantine alone (n=8) 1.02 (0.41, 2.53)  2.05 (0.62, 6.78)  
AChE-inhibitor alone (n=105) 0.41 (0.27, 0.62)  0.59 (0.28, 1.23)  
Both (n=26) 0.57 (0.33, 0.97)  0.81 (0.32, 2.09)  
Neither (n=164) Reference    
Type of medication (n=251)  0.0001  0.165 
Donepezil (n=31) 0.22 (0.09, 0.54)  0.50 (0.17, 1.50)  
Rivastigmine (n=41) 0.71 (0.42, 1.19)  0.58 (0.25, 1.35)  
Galantamine (n=51) 0.44 (0.27, 0.70)  0.55 (0.23, 1.31)  
Combination of drug (n=9)† 0.26 (0.10, 0.73)  0.26 (0.08, 0.85)  
Neither (n=171) Reference  Reference  
 
† Some subjects are on two medications: donepezil and rivastigmine (n=1), donepezil and 
galantamine (n=1), and rivastigmine and galantamine (n=7) 
 




Table 3 - Estimate of the effects of anti-dementia medication on DLD scores at first and 
second assessment, estimated from a multiple linear regression model 
DLD Coefficient* 95% Confidence Interval p-value 
Cognition score (SCS)    
Baseline (n=125) -0.074 -2.87 to 2.72 0.958 
1st assessment (n=110) -4.37 -8.53  to -0.21 0.040 
2nd assessment (n=95) 0.24 -4.76 to  5.25 0.923 
Social score (SSS)    
Baseline (n=124) -1.34 -4.90 to 2.22 0.458 
1st assessment (n=102) -2.70 -7.78 to 2.39 0.295 
2nd assessment (n=92) -0.05 -4.70 to 4.60 0.983 
 
*Regression coefficient adjusted for pre-treatment score.  The coefficient represents the 
mean difference (on medication - not on medication)  
 
